We are a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.

Precision genome editing

Our next-generation CRISPR genome-editing technology enables superior specificity and precision. Our patented chRDNA (CRISPR hybrid RNA-DNA) technology drives for complex genome editing, including multiplex gene knockout and insertion, while maintaining genomic integrity.

Learn about chRDNA

Off-the-shelf cell therapies

We are developing allogeneic, or off-the-shelf, CAR-T and CAR-NK cell therapies from healthy donor cells to address the limitations of currently approved therapies.

View our pipeline

Armored for enhanced activity

We believe armoring is the key to unlocking the full potential of allogeneic cell therapies. We use our chRDNA technologies to armor our cell therapies through multiple genome-editing strategies, including checkpoint disruption, immune cloaking, or a combination of these two strategies, to enhance activity against devastating diseases.

Armoring for activity

“Caribou is a leader in the CRISPR field, successfully leveraging its proprietary genome-editing technologies to develop allogeneic cell therapies that are potentially transformative for patients.”

Jennifer Doudna, PhD
Co-founder of Caribou
Co-recipient of the 2020 Nobel Prize in Chemistry

Join the Herd

Caribou Biosciences is a pioneer in genome editing and cell therapy development, and we are seeking talented and passionate individuals to join our team.

Working at Caribou

caribou image